ME03053B - Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine - Google Patents
Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotineInfo
- Publication number
- ME03053B ME03053B MEP-2018-184A MEP18418A ME03053B ME 03053 B ME03053 B ME 03053B ME P18418 A MEP18418 A ME P18418A ME 03053 B ME03053 B ME 03053B
- Authority
- ME
- Montenegro
- Prior art keywords
- rotigotine
- polyvinylpyrrolidone
- stabilization
- crystalline form
- solid dispersion
- Prior art date
Links
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 title 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 title 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 title 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 title 1
- 229960003179 rotigotine Drugs 0.000 title 1
- 239000007962 solid dispersion Substances 0.000 title 1
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28930209P | 2009-12-22 | 2009-12-22 | |
| PCT/EP2010/070563 WO2011076879A1 (en) | 2009-12-22 | 2010-12-22 | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
| EP10796399.3A EP2515887B1 (en) | 2009-12-22 | 2010-12-22 | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03053B true ME03053B (en) | 2018-10-20 |
Family
ID=43568293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2018-184A ME03053B (en) | 2009-12-22 | 2010-12-22 | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9925150B2 (en) |
| EP (3) | EP4403172A3 (en) |
| JP (1) | JP5815556B2 (en) |
| KR (3) | KR20160055971A (en) |
| CN (3) | CN102665699A (en) |
| AU (1) | AU2010334805B2 (en) |
| BR (1) | BR112012017737A8 (en) |
| CA (1) | CA2767068C (en) |
| CY (1) | CY1120621T1 (en) |
| DK (2) | DK2515887T3 (en) |
| EA (1) | EA025584B1 (en) |
| ES (2) | ES2679800T3 (en) |
| FI (1) | FI3257504T3 (en) |
| HK (1) | HK1200335A1 (en) |
| HR (2) | HRP20181173T1 (en) |
| HU (2) | HUE067921T2 (en) |
| IL (1) | IL219091A (en) |
| LT (2) | LT3257504T (en) |
| ME (1) | ME03053B (en) |
| MX (1) | MX2012007326A (en) |
| PL (2) | PL3257504T3 (en) |
| PT (2) | PT2515887T (en) |
| RS (2) | RS57457B1 (en) |
| SI (2) | SI3257504T1 (en) |
| SM (2) | SMT201800430T1 (en) |
| TR (1) | TR201810322T4 (en) |
| WO (1) | WO2011076879A1 (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19814084B4 (en) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation |
| DE10234673B4 (en) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS |
| DE10334188B4 (en) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Use of rotigotine to treat depression |
| DE10334187A1 (en) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituted 2-aminotetralins for the treatment of depression |
| DE10359528A1 (en) * | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S) -2-N-propylamino-5-hydroxytetralin as a D3 agonist therapeutic |
| US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
| SI2215072T1 (en) | 2007-11-28 | 2015-10-30 | Ucb Pharma Gmbh | Polymorphic form of rotigotine |
| EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| US9925150B2 (en) | 2009-12-22 | 2018-03-27 | Lts Lohmann Therapie-Systeme Ag | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
| WO2012084969A1 (en) | 2010-12-22 | 2012-06-28 | Hexal Ag | Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition |
| EP2559435A1 (en) * | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
| WO2013075822A1 (en) | 2011-11-22 | 2013-05-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system (tts) with rotigotine |
| DE102012013421A1 (en) | 2012-07-03 | 2014-01-09 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system useful for treating, alleviating and/or preventing e.g. Parkinson's disease, depression, comprises backing layer, matrix layer comprising rotigotine, and protection film applied to part of matrix layer surface |
| DE102011119043A1 (en) | 2011-11-22 | 2013-05-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system comprises an active substance-impermeable backing layer, self-adhesive reservoir with content of active substance, which is rotigotine or rotigotine derivative, and a removable protective layer |
| DE102011090178A1 (en) | 2011-12-30 | 2013-07-04 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with low tendency to spontaneous crystallization |
| KR101558042B1 (en) | 2012-07-05 | 2015-10-07 | 에스케이케미칼주식회사 | Transdermal composition comprising rotigotine |
| KR101558043B1 (en) * | 2012-07-06 | 2015-10-07 | 에스케이케미칼주식회사 | Transdermal composition comprising rotigotine |
| TW201431570A (en) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | Multi-day patch for the transdermal administration of rotigotine |
| EP3016641B1 (en) | 2013-07-03 | 2018-09-05 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system having an electronic component |
| WO2015177209A1 (en) * | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
| EP3145502B1 (en) | 2014-05-20 | 2022-07-06 | LTS Lohmann Therapie-Systeme AG | Transdermal delivery system containing rotigotine |
| US11752110B2 (en) * | 2014-05-20 | 2023-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| KR102364378B1 (en) | 2014-05-21 | 2022-02-16 | 에스케이케미칼 주식회사 | Transdermal composition comprising rotigotine with improved the stability |
| DE102014114282A1 (en) * | 2014-10-01 | 2016-04-07 | Neuraxpharm Arzneimittel Gmbh | Transdermal therapeutic system with rotigotine for the treatment of Parkinson's disease |
| CN104382850B (en) * | 2014-10-17 | 2017-12-22 | 烟台大学 | A kind of rotigotine micro emulsion and micro emulsion gel |
| WO2017136303A1 (en) * | 2016-02-05 | 2017-08-10 | 3M Innovative Properties Company | Transdermal drug delivery systems with fluorosilicone release liners |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2018143384A1 (en) * | 2017-02-03 | 2018-08-09 | コスメディ製薬株式会社 | Rotigotine-containing percutaneous absorption type patch |
| ES2900255T3 (en) | 2017-09-04 | 2022-03-16 | Lts Lohmann Therapie Systeme Ag | Transdermal delivery system including an emulsifier |
| KR102363218B1 (en) | 2017-12-19 | 2022-02-14 | 히사미쓰 세이야꾸 가부시키가이샤 | Rotigotine-containing patch |
| KR102731700B1 (en) | 2018-10-24 | 2024-11-15 | 에스케이케미칼 주식회사 | Composition comprising non-crystalline rotigotine and manufacturing method thereof |
| CN113453676B (en) | 2019-02-15 | 2025-08-05 | 久光制药株式会社 | Rotigotine stabilization method |
| JP7688036B2 (en) * | 2019-12-20 | 2025-06-03 | エルテーエス ローマン テラピー－ジステーメ アーゲー | Transdermal Therapeutic System Containing Agomelatine |
| DK3854388T3 (en) * | 2020-01-24 | 2023-11-27 | Luye Pharma Switzerland Ag | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING ROTIGOTIN AND AT LEAST ONE NON-AMININE-RESISTANT SILICONE ADHESIVE |
| CN112089686A (en) * | 2020-10-12 | 2020-12-18 | 郑鉴忠 | Method for producing free drug mucous membrane skin administration preparation |
| WO2024040860A1 (en) * | 2022-08-24 | 2024-02-29 | 新领医药技术(深圳)有限公司 | Rotigotine transdermal drug delivery system inhibiting crystallization, method for preparing same, and use thereof |
| CN120417892A (en) | 2022-12-26 | 2025-08-01 | 丸仁制药株式会社 | Transdermal absorption preparation and preparation method thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5177112A (en) | 1983-01-03 | 1993-01-05 | Whitby Research, Inc. | Substituted 2-aminotetralins |
| US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5308887A (en) * | 1991-05-23 | 1994-05-03 | Minnesota Mining & Manufacturing Company | Pressure-sensitive adhesives |
| US5676968A (en) | 1991-10-31 | 1997-10-14 | Schering Aktiengesellschaft | Transdermal therapeutic systems with crystallization inhibitors |
| US5989586A (en) | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
| US5382596A (en) | 1993-08-05 | 1995-01-17 | Whitby Research, Inc. | Substituted 2-aminotetralins |
| US6713300B1 (en) * | 1997-02-27 | 2004-03-30 | University Of Utah Research Foundation | Nucleic acid and amino acid sequences for ATP-binding cassette transporter and methods of screening for agents that modify ATP-binding cassette transporter |
| DE19814084B4 (en) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation |
| HK1049156B (en) | 1999-11-23 | 2004-12-10 | Ucb Manufacturing Ireland Limited | Improved process for preparing nitrogen-substituted aminotetralins |
| LU90623B1 (en) | 2000-08-04 | 2002-02-05 | Trefilarbed Bissen Sa | Method and installation for coating wire material |
| DE10041479A1 (en) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | New pharmaceutical composition for the administration of N-0923 |
| DE10041478A1 (en) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | New pharmaceutical composition |
| EP1256340B1 (en) | 2001-05-08 | 2003-08-13 | Schwarz Pharma Ag | Improved transdermal therapeutic system for the treatment of Parkinson's disease |
| US20030027793A1 (en) | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
| PT1256339E (en) | 2001-05-08 | 2004-02-27 | Lohmann Therapie Syst Lts | TRANSDERMIC THERAPEUTIC SYSTEM FOR PARKINSON'S DISEASE INDUCING HIGH PLASMATIC NORMS OF ROTIGOTINE |
| US20030026830A1 (en) | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
| FR2829028B1 (en) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | COMBINATION OF AN ANTAGONIST OF THE CB1 RECEPTOR AND A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF DISEASE |
| US20060263419A1 (en) | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
| EP1494664A2 (en) | 2002-04-18 | 2005-01-12 | Pharmacia Corporation | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease |
| DE10220230A1 (en) * | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Use of Rotigotine to treat restless leg syndrome |
| US20040048779A1 (en) | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
| US20060216336A1 (en) | 2002-05-07 | 2006-09-28 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
| DE60318446T2 (en) * | 2002-07-15 | 2008-05-21 | Alcon Inc. | NON-POLYMERS LIPOPHILIC PHARMACEUTICAL IMPLANT COMPOSITIONS FOR INTRA-OXULAR APPLICATION |
| EP1386604A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system |
| US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| DE10234673B4 (en) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS |
| US8246980B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| EP1386605A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system for the administration of rotigotine |
| ATE295726T1 (en) | 2002-12-02 | 2005-06-15 | Sanol Arznei Schwarz Gmbh | ADMINISTRATION OF ROTIGOTINE FOR THE TREATMENT OF PARKINSON'S DISEASE BY IONTOPHORESIS |
| DE10261696A1 (en) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Device for the transdermal administration of rotigotine base |
| DE10334188B4 (en) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Use of rotigotine to treat depression |
| DE10334187A1 (en) | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituted 2-aminotetralins for the treatment of depression |
| DE10359528A1 (en) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S) -2-N-propylamino-5-hydroxytetralin as a D3 agonist therapeutic |
| EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
| DE10361258A1 (en) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Use of substituted 2-aminotetralins for the preventive treatment of Parkinson's disease |
| DE10361259A1 (en) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Use of Rotigotine in Early Stage Parkinson's Disease to Prevent Further Neuronal Loss |
| US20050197385A1 (en) | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
| DE102004014841B4 (en) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Use of rotigotine for the treatment and prevention of Parkinson-Plus syndrome |
| US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
| TWI392670B (en) | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain |
| US20080226698A1 (en) | 2007-03-16 | 2008-09-18 | Mylan Technologies, Inc. | Amorphous drug transdermal systems, manufacturing methods, and stabilization |
| EP1987815A1 (en) | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| CN101147739B (en) * | 2007-07-06 | 2010-12-08 | 北京康倍得医药技术开发有限公司 | Composition containing rotigotine and its use and transdermal patch containing the composition |
| ATE457247T1 (en) | 2007-11-27 | 2010-02-15 | Delphi Tech Inc | DEVICE AND METHOD FOR FOLDING AN AIR BAG |
| SI2215072T1 (en) | 2007-11-28 | 2015-10-30 | Ucb Pharma Gmbh | Polymorphic form of rotigotine |
| US20090202647A1 (en) * | 2008-02-11 | 2009-08-13 | Mayur Devjibhai Khunt | Solid form of racemic rotigotine |
| WO2009158120A2 (en) | 2008-05-30 | 2009-12-30 | Mylan Laboratories Inc. | Stabilized transdermal drug delivery system |
| EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| US9925150B2 (en) | 2009-12-22 | 2018-03-27 | Lts Lohmann Therapie-Systeme Ag | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
-
2010
- 2010-12-22 US US13/515,067 patent/US9925150B2/en active Active
- 2010-12-22 EP EP24179248.0A patent/EP4403172A3/en active Pending
- 2010-12-22 CN CN2010800513394A patent/CN102665699A/en active Pending
- 2010-12-22 ES ES10796399.3T patent/ES2679800T3/en active Active
- 2010-12-22 LT LTEP17185284.1T patent/LT3257504T/en unknown
- 2010-12-22 ES ES17185284T patent/ES2983178T3/en active Active
- 2010-12-22 BR BR112012017737A patent/BR112012017737A8/en not_active Application Discontinuation
- 2010-12-22 DK DK10796399.3T patent/DK2515887T3/en active
- 2010-12-22 KR KR1020167011866A patent/KR20160055971A/en not_active Withdrawn
- 2010-12-22 AU AU2010334805A patent/AU2010334805B2/en active Active
- 2010-12-22 LT LTEP10796399.3T patent/LT2515887T/en unknown
- 2010-12-22 SM SM20180430T patent/SMT201800430T1/en unknown
- 2010-12-22 HR HRP20181173TT patent/HRP20181173T1/en unknown
- 2010-12-22 PL PL17185284.1T patent/PL3257504T3/en unknown
- 2010-12-22 TR TR2018/10322T patent/TR201810322T4/en unknown
- 2010-12-22 WO PCT/EP2010/070563 patent/WO2011076879A1/en not_active Ceased
- 2010-12-22 HU HUE17185284A patent/HUE067921T2/en unknown
- 2010-12-22 EA EA201270657A patent/EA025584B1/en not_active IP Right Cessation
- 2010-12-22 DK DK17185284.1T patent/DK3257504T3/en active
- 2010-12-22 CN CN201610412864.3A patent/CN105997952A/en active Pending
- 2010-12-22 PT PT10796399T patent/PT2515887T/en unknown
- 2010-12-22 RS RS20180850A patent/RS57457B1/en unknown
- 2010-12-22 PL PL10796399T patent/PL2515887T3/en unknown
- 2010-12-22 SI SI201032150T patent/SI3257504T1/en unknown
- 2010-12-22 MX MX2012007326A patent/MX2012007326A/en unknown
- 2010-12-22 FI FIEP17185284.1T patent/FI3257504T3/en active
- 2010-12-22 CN CN201410448874.3A patent/CN104189912A/en active Pending
- 2010-12-22 RS RS20240882A patent/RS65853B1/en unknown
- 2010-12-22 JP JP2012545332A patent/JP5815556B2/en active Active
- 2010-12-22 SM SM20240353T patent/SMT202400353T1/en unknown
- 2010-12-22 ME MEP-2018-184A patent/ME03053B/en unknown
- 2010-12-22 HU HUE10796399A patent/HUE039447T2/en unknown
- 2010-12-22 EP EP10796399.3A patent/EP2515887B1/en active Active
- 2010-12-22 HR HRP20241060TT patent/HRP20241060T1/en unknown
- 2010-12-22 EP EP17185284.1A patent/EP3257504B1/en active Active
- 2010-12-22 KR KR1020127016095A patent/KR101807721B1/en active Active
- 2010-12-22 CA CA2767068A patent/CA2767068C/en active Active
- 2010-12-22 KR KR1020167025041A patent/KR20170023772A/en not_active Ceased
- 2010-12-22 PT PT171852841T patent/PT3257504T/en unknown
- 2010-12-22 SI SI201031744T patent/SI2515887T1/en unknown
-
2012
- 2012-04-05 IL IL219091A patent/IL219091A/en active IP Right Grant
-
2015
- 2015-01-23 HK HK15100819.2A patent/HK1200335A1/en unknown
-
2018
- 2018-01-31 US US15/884,587 patent/US10130589B2/en active Active
- 2018-05-17 US US15/982,744 patent/US10350174B2/en active Active
- 2018-08-24 CY CY181100885T patent/CY1120621T1/en unknown
-
2019
- 2019-05-23 US US16/420,501 patent/US20190314294A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL219091A0 (en) | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine | |
| EP2490632B8 (en) | Contraceptive devices | |
| IL217153A0 (en) | Controlled release formulations | |
| EP2484409A4 (en) | Mask | |
| EP2407209A4 (en) | Mask | |
| ZA201106050B (en) | Dye-polymers formulations | |
| AU330863S (en) | Earplug | |
| PL2241447T3 (en) | Self-colouring hand stamp | |
| PL2496340T3 (en) | Silica dispersion | |
| GB0922610D0 (en) | Earphone | |
| GB0919210D0 (en) | Formulations | |
| GB0905702D0 (en) | Headset | |
| GB2466345B (en) | Brick protector | |
| GB2479500B (en) | Roaming printing | |
| TWM402794U (en) | Stamp | |
| IL217390A0 (en) | Formulations | |
| GB0908584D0 (en) | Adjusting device | |
| AU329299S (en) | Headset | |
| GB0909780D0 (en) | Ha as a chrondrogenic differentiation agent | |
| GB0909037D0 (en) | Ultimate Plug | |
| TWM372198U (en) | Mask | |
| IL199526A0 (en) | Mask | |
| GB0904386D0 (en) | Antitumoral compounds | |
| EM10964570001S (en) | Breathing devices | |
| TWM369758U (en) | Nano-energetic eye mask |